Cigna Investments Inc. New reduced its position in shares of Amedisys Inc (NASDAQ:AMED) by 26.9% in the 1st quarter, Holdings Channel reports. The firm owned 3,806 shares of the health services provider’s stock after selling 1,403 shares during the period. Cigna Investments Inc. New’s holdings in Amedisys were worth $470,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in Amedisys in the fourth quarter valued at $68,342,000. Vanguard Group Inc increased its stake in Amedisys by 14.3% in the third quarter. Vanguard Group Inc now owns 3,326,180 shares of the health services provider’s stock valued at $415,640,000 after purchasing an additional 415,060 shares during the period. MERIAN GLOBAL INVESTORS UK Ltd increased its stake in Amedisys by 536.4% in the fourth quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 268,731 shares of the health services provider’s stock valued at $31,471,000 after purchasing an additional 226,504 shares during the period. Acadian Asset Management LLC increased its stake in Amedisys by 31.6% in the fourth quarter. Acadian Asset Management LLC now owns 802,138 shares of the health services provider’s stock valued at $93,940,000 after purchasing an additional 192,552 shares during the period. Finally, Millennium Management LLC increased its stake in Amedisys by 66.2% in the fourth quarter. Millennium Management LLC now owns 222,513 shares of the health services provider’s stock valued at $26,058,000 after purchasing an additional 88,634 shares during the period. 86.30% of the stock is owned by institutional investors and hedge funds.

AMED stock opened at $112.31 on Monday. The stock has a market cap of $3.60 billion, a P/E ratio of 30.94, a P/E/G ratio of 1.40 and a beta of 1.40. Amedisys Inc has a 52 week low of $73.97 and a 52 week high of $140.91. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.69.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Tuesday, April 30th. The health services provider reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.22. Amedisys had a net margin of 7.14% and a return on equity of 28.25%. The company had revenue of $467.34 million for the quarter, compared to the consensus estimate of $460.83 million. During the same quarter in the prior year, the firm earned $0.79 earnings per share. The company’s revenue for the quarter was up 17.0% compared to the same quarter last year. On average, equities analysts predict that Amedisys Inc will post 4.08 earnings per share for the current year.

A number of research analysts have commented on AMED shares. Zacks Investment Research lowered shares of Amedisys from a “buy” rating to a “hold” rating in a research note on Monday, February 4th. ValuEngine upgraded shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Monday, February 4th. Benchmark lowered shares of Amedisys from a “buy” rating to a “hold” rating and set a $136.64 price objective on the stock. in a research note on Tuesday, February 5th. BidaskClub upgraded shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 14th. Finally, SunTrust Banks boosted their price target on shares of Amedisys to $145.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the stock. Amedisys presently has an average rating of “Hold” and a consensus target price of $125.90.

In other Amedisys news, insider David B. Pearce sold 4,370 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $120.01, for a total value of $524,443.70. Following the sale, the insider now owns 13,129 shares of the company’s stock, valued at $1,575,611.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bruce D. Perkins purchased 2,500 shares of Amedisys stock in a transaction on Wednesday, May 15th. The stock was acquired at an average cost of $111.84 per share, for a total transaction of $279,600.00. Following the acquisition, the director now directly owns 22,088 shares of the company’s stock, valued at $2,470,321.92. The disclosure for this purchase can be found here. Insiders sold 21,870 shares of company stock worth $2,538,494 in the last ninety days. Insiders own 2.90% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Amedisys Inc (AMED) Stake Lessened by Cigna Investments Inc. New” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/amedisys-inc-amed-stake-lessened-by-cigna-investments-inc-new/3029980.html.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Story: Return on Investment (ROI)

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.